Identification of genotype-biochemical phenotype correlations associated with fructose 1,6-bisphosphatase deficiency

Fructose-1,6-bisphosphatase (FBPase) deficiency, caused by an FBP1 mutation, is an autosomal recessive disorder characterized by hypoglycemic lactic acidosis. Due to the rarity of FBPase deficiency, the mechanism by which the mutations cause enzyme activity loss still remains unclear. Here we identify compound heterozygous missense mutations of FBP1, c.491G>A (p.G164D) and c.581T>C (p.F194S), in an adult patient with hypoglycemic lactic acidosis. The G164D and F194S FBP1 mutants exhibit decreased FBP1 protein expression and a loss of FBPase enzyme activity. The biochemical phenotypes of all previously reported FBP1 missense mutations in addition to G164D and F194S are classified into three functional categories. Type 1 mutations are located at pivotal residues in enzyme activity motifs and have no effects on protein expression. Type 2 mutations structurally cluster around the substrate binding pocket and are associated with decreased protein expression due to protein misfolding. Type 3 mutations are likely nonpathogenic. These findings demonstrate a key role of protein misfolding in mediating the pathogenesis of FBPase deficiency, particularly for Type 2 mutations. This study provides important insights that certain patients with Type 2 mutations may respond to chaperone molecules. Genotype-biochemical phenotype correlation suggests protein misfolding plays a key role in pathogenesis of fructose-1,6-bisphosphatase deficiency for one functional class of missense mutations reported in the associated enzyme.

Automated summary

Fructose-1,6-bisphosphatase (FBPase) deficiency, caused by an FBP1 mutation, is a rare disease characterized by hypoglycemic lactic acidosis. This study identified compound heterozygous missense mutations of FBP1 in an adult patient, which resulted in decreased protein expression and loss of enzyme activity. The findings suggest that protein misfolding plays a key role in the pathogenesis of FBPase deficiency, particularly for Type 2 mutations.